TABLE 3.
Postoperative outcomes.
| Overall (n = 36) | PCD (n = 19) | PCD + SA (n = 17) | p-value | |||||
|---|---|---|---|---|---|---|---|---|
| Median | [IQR] | Median | [IQR] | Median | [IQR] | |||
| ICU length of stay (days) | 7 | [4–14] | 5 | [2–11] | 12 | [7–26] | 0.029 | |
| Total length of stay (days) | 31.5 | [20–45] | 26 | [20–42] | 41 | [19–55] | 0.114 | |
| Percent predicted FEV1 | ||||||||
| 3 months | 77 | [61–86] | 73.5 | [61–85] | 80 | [64–87] | 0.734 | |
| 6 months | 80 | [63–92] | 83 | [57–92] | 77 | [68–92] | 0.550 | |
| 1 year | 80 | [57–90] | 80 | [57–90] | 91 | [62.3–90] | 0.864 | |
| Latest | 70 | [41–88] | 74 | [46–97] | 56 | [36–76] | 0.233 | |
| n | % | n | % | n | % | p-value | ||
| PGD at 24 h a | ||||||||
| PGD 0 | 17 | 47.2 | 7 | 36.8 | 10 | 58.8 | 0.407 | |
| PGD 1 | 11 | 30.6 | 8 | 42.1 | 3 | 17.6 | ||
| PGD 2 | 4 | 11.1 | 2 | 10.5 | 2 | 11.8 | ||
| PGD 3 | 3 | 8.3 | 2 | 10.5 | 1 | 5.9 | ||
| PGD at 48 h a | ||||||||
| PGD 0 | 17 | 47.2 | 6 | 31.6 | 11 | 64.7 | 0.067 | |
| PGD 1 | 14 | 38.9 | 11 | 57.9 | 3 | 17.6 | ||
| PGD 2 | 3 | 8.3 | 2 | 10.5 | 1 | 5.9 | ||
| PGD 3 | 1 | 2.8 | 0 | 0.0 | 1 | 5.9 | ||
| PGD at 72 h a | ||||||||
| PGD 0 | 18 | 50.0 | 7 | 36.8 | 11 | 64.7 | 0.371 | |
| PGD 1 | 11 | 30.6 | 8 | 42.1 | 3 | 17.6 | ||
| PGD 2 | 3 | 8.3 | 2 | 10.5 | 1 | 5.9 | ||
| PGD 3 | 2 | 5.6 | 1 | 5.3 | 1 | 5.9 | ||
| Rejection ≥A2 on first biopsy | 9 | 25.0 | 3 | 15.8 | 6 | 35.3 | 0.177 | |
| Rejection ≥A2 within first year | 6 | 16.7 | 1 | 5.3 | 5 | 29.4 | 0.052 | |
| CLAD | 13 | 36.1 | 5 | 26.3 | 8 | 47.1 | 0.196 | |
a
Data from a PCD + SA patient is not available.
PCD, primary ciliary dyskinesia; SA, situs abnormalities; ICU, intensive care unit; FEV1, forced expiratory volume at 1 s; PGD, primary graft dysfunction; CLAD, chronic lung allograft dysfunction.